Are So-Called Uremic Toxins Always Toxic?

Journal of Renal Nutrition

Volumn 18, Issue 1, 2008, Pages 7-11

  Rutkowski, Przemysław ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

L METHYL 2 PYRIDONE 5 CARBOXAMIDE; L-METHYL-2-PYRIDONE-5-CARBOXAMIDE; PYRIDONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; BLOOD; CELL LINE; CELL SURVIVAL; CHEMICALLY INDUCED DISORDER; COMET ASSAY; DISEASE MODEL; DRUG EFFECT; HUMAN; KIDNEY; LEUKEMIA L 5178 Y; LIVER; METHODOLOGY; MOUSE; PATHOLOGY; RAT; UREMIA;

ANIMALS; CELL LINE; CELL SURVIVAL; COMET ASSAY; DISEASE MODELS, ANIMAL; HUMANS; KIDNEY; LEUKEMIA L5178; LIVER; MICE; PYRIDONES; RATS; UREMIA;

EID: 37049002210     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2007.10.004     Document Type: Article

References (44)

1. Massry S.G. Is parathyroid hormone a uremic toxin?. Nephron 19 (1977) 125-130
2. Johnson W., Hagge W., Wagoner R., et al. Effects of urea loading in patients with far-advanced renal failure. Mayo Clin Proc 47 (1972) 21-29
3. Bergstrom J., and Furst P. Uremic toxins. Kidney Int 13 Suppl 8 (1978) S9-S12
4. Tanaka A., Takahashi Y., Mizokuchi M., et al. Plasma, urinary, and erythrocyte concentrations of guanidino compounds in patients with chronic renal failure. Ren Fail 21 (1999) 499-514
5. De Deyn P.P., D'Hooge R., Van Bogaert P.P., et al. Endogenous guanidino compounds as uremic neurotoxins. Kidney Int 59 (2001) 77-83
6. Deppisch R.M., Beck W., Goehl H., et al. Complement components as uremic toxins and their potential role as mediators of microinflammation. Kidney Int 78 Suppl (2001) S271-S277
7. Pawlak D., Tankiewicz A., and Buczko W. Kynurenine and its metabolites in the rat with experimental renal insufficiency. J Physiol Pharmacol 52 (2001) 755-766
8. Pawlak D., Pawlak K., Malyszko J., et al. Accumulation of toxic products degradation of kynurenine in hemodialyzed patients. Int Urol Nephrol 33 (2001) 399-404
9. Schwenger V., Zeier M., Henle T., et al. Advanced glycation endproducts (AGEs) as uremic toxins. Nahrung 45 (2001) 172-176
10. McGregor D.O., Dellow W.J., Lever M., et al. Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations. Kidney Int 59 (2001) 2267-2272
11. Bullo B., Marlewski M., Smolenski R.T., et al. Erythrocyte nucleotides and blood hypoxanthine in patients with uremia evaluated immediately and 24 hours after hemodialysis. Ren Fail 18 (1996) 247-252
12. Yu P., and Dyck R. Impairment of methylamine clearance in uremic patients and its nephropathological implications. Clin Nephrol 49 (1998) 299-302
13. Dhondt A., Vanholder R., Van Biesen W., et al. The removal of uremic toxins. Kidney Int (Suppl) 76 (2000) S47-S59
14. Int S., Clark W.R., and Gao D. Low-molecular weight proteins in end-stage renal disease: potential toxicity and dialytic removal mechanisms. J Am Soc Nephrol 13 Suppl 1 (2002) S41-S47
15. Vanholder R., De Smet R., and Lameire N.H. Redesigning the map of uremic toxins. Contrib Nephrol 133 (2001) 42-70
16. Vanholder R., De Smet R., Glorieux G., et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 63 (2003) 1934-1943
17. Rutkowski B., Slominska E., Szolkiewicz M., et al. N-methyl-2-pyridone-5-carboxamide: a novel uremic toxin?. Kidney Int 84 Suppl (2003) S19-S21
18. Slominska E.M., Smolenski R., Szolkiewicz M., et al. Accumulation of plasma N-methyl-2-pyridone-5-carboxamide in patients with chronic renal failure. Mol Cell Biochem 231 (2002) 83-88
19. Slominska E.M., Kowalik K., Smolenski R.T., et al. Accumulation of poly(ADP-ribose) polymerase inhibitors in children with chronic renal failure. Pediatr Nephrol 21 (2006) 800-806
20. Rutkowski B., Swierczynski J., Slominska E., et al. Disturbances of purine nucleotide metabolism in uremia. Semin Nephrol 24 (2004) 479-483
21. Rutkowski P., Malgorzewicz S., Slominska E., et al. Interrelationship between uremic toxicity and oxidative stress. J Ren Nutr 16 (2006) 190-193
22. Rutkowski P., and Rutkowski B. Novel family of uremic toxins. Nephrol Dial Pol 10 (2006) 152-155
23. Rutkowski P., Slominska E.M., Szolkiewicz M., et al. Relationship between uremic toxins and oxidative stress in patients with chronic renal failure. Scand J Urol Nephrol 41 (2007) 243-248
24. Slominska E.M., Smolenski R.T., Osborne F., et al. The effect of N-methyl-2-pyridone-5-carboxamide-a nicotinamide catabolite on poly ADP-rybosylation and oxidative stress injury in endothelial cells. Nucleosides Nucleotides Nucleic Acids 24 (2005) 259-262
25. Ollikainen T., Puhakka A., Kahlos K., et al. Modulation of cell and DNA damage by poly(ADP)ribose polymerase in lung cells exposed to H(2)O(2) or asbestos fibres. Mutat Res 470 (2000) 77-84
26. Schupp N., Schmid U., Rutkowski P., et al. Angiotensin II-induced genomic damage in renal cells can be prevented by angiotensin II type 1 receptor blockage or radical scavenging. Am J Physiol Ren Physiol 292 (2007) F1427-F1434
27. Singh N., McCoy M., Tice R., et al. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175 (1988) 184-191
28. Schwarz A., Maeda A., Kernebeck K., et al. Prevention of UV radiation-induced immunosuppression by IL-12 is dependent on DNA repair. J Exp Med 201 (2005) 173-179
29. Dantzer F., Ame J.C., Schreiber V., et al. Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair. Methods Enzymol 409 (2006) 493-510
30. Ame J.C., Spenlehauer C., and de Murcia G. The PARP superfamily. Bioessays 26 (2004) 882-893
31. Palfi A., Toth A., Hanto K., et al. PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway. J Mol Cell Cardiol 41 (2006) 149-159
32. Yeh C.H., Chen T.P., Lee C.H., et al. Inhibition of poly(ADP-ribose) polymerase reduces cardiomyocytic apoptosis after global cardiac arrest under cardiopulmonary bypass. Shock 25 (2006) 168-175
33. Olusegun Fayemi A., and Ali M. Malignant neoplasms in long-term hemodialysis patients. J Med Soc NJ 76 (1979) 497-500
34. Kinlen L.J., Eastwood J.B., Kerr D.N., et al. Cancer in patients receiving dialysis. Br Med J [Clin Res] 280 (1980) 1401-1403
35. Port F.K., Ragheb N.E., Schwartz A.G., et al. Neoplasms in dialysis patients: a population-based study. Am J Kidney Dis 14 (1989) 119-123
36. Pecqueux J.C., Schwarz A., Dieckmann K.P., et al. Cancer incidence in patients on chronic dialysis and in renal transplant recipients. Urol Int 45 (1990) 290-292
37. Maisonneuve P., Agodoa L., Gellert R., et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 354 (1999) 93-99
38. Newstead C.G. Cancer risk in patients on dialysis. Lancet 354 (1999) 90-91
39. Bargman J.M. Neoplasia in dialysis patients: pathophysiology, epidemiology, and screening. Adv Perit Dial 16 (2000) 93-96
40. Teschner M., Garte C., Ruckle-Lanz H., et al. Incidence and spectrum of malignant disease among dialysis patients in North Bavaria. [in German]. Dtsch Med Wochenschr 127 (2002) 2497-2502
41. Price J.M. The determination of N-methyl-2-pyridone-5-carboxamide in human urine. J Biol Chem 211 (1954) 117-124
42. Walters C.J., Brown R.R., Kaihara M., et al. The excretion of N-methyl-2-pyridone-5-carboxamide by man following ingestion of several known or potential precursors. J Biol Chem 217 (1955) 489-495
43. Abelson D., Boyle A., Depatie C., et al. N′-methyl-2-pyridone-5-carboxamide in human plasma. Clin Chim Acta 82 (1963) 603-606
44. Rutkowski P., Ochocinska J., Slominska E., et al. Saliva excretion of n-methyl-2-pyridone-5-carboxamide in patients with chronic renal insufficiency. Ren Fail (2007) (accepted)